Found: 13
Select item for more details and to access through your institution.
Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Receptor Phosphorylation of Melanoma Cells But Does Not Affect Tumorigenicity In Vivo.
- Published in:
- Journal of Investigative Dermatology, 2004, v. 122, n. 2, p. 400, doi. 10.1046/j.0022-202X.2004.22231.x
- By:
- Publication type:
- Article
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
- Published in:
- Journal of Translational Medicine, 2010, v. 8, p. 9, doi. 10.1186/1479-5876-8-9
- By:
- Publication type:
- Article
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec<sup>TM</sup>).
- Published in:
- Journal of Cutaneous Pathology, 2006, v. 33, n. 4, p. 280, doi. 10.1111/j.0303-6987.2006.00432.x
- By:
- Publication type:
- Article
Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array.
- Published in:
- Journal of Cutaneous Pathology, 2003, v. 30, n. 9, p. 539, doi. 10.1034/j.1600-0560.2003.00090.x
- By:
- Publication type:
- Article
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 4, p. 945, doi. 10.1007/s00280-010-1377-y
- By:
- Publication type:
- Article
Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF<sup>V600E</sup> Mutated Papillary Thyroid Cancer: Two Case Reports.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
- Published in:
- 1996
- By:
- Publication type:
- journal article
Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.
- Published in:
- Cancer (0008543X), 1996, v. 77, n. 1, p. 89, doi. 10.1002/(SICI)1097-0142(19960101)77:1<89::AID-CNCR15>3.0.CO;2-4
- By:
- Publication type:
- Article
Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanomaPresented in part as a poster (abstract 2865) at the Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois, May 31–June 3, 2003.: Significant toxicity with no clinical efficacy
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 9, p. 2005
- By:
- Publication type:
- Article
Pilot study of high‐dose, concurrent biochemotherapy for advanced melanomaSee editorial on pages 435–8, this issue.
- Published in:
- Cancer (0008543X), 2004, v. 101, n. 3, p. 596
- By:
- Publication type:
- Article
Biochemotherapy in patients with metastatic anorectal mucosal melanoma.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 7, p. 1478
- By:
- Publication type:
- Article
Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
- Published in:
- Cancer (0008543X), 2002, v. 95, n. 1, p. 127, doi. 10.1002/cncr.10631
- By:
- Publication type:
- Article
A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.
- Published in:
- 2000
- By:
- Publication type:
- journal article